Clinical significance of cancer stem cell markers in lung carcinoma

Liang  Zhang; Lianglan  Shen; Dijun Wu

doi:10.18388/abp.2020_5498

Clinical significance of cancer stem cell markers in lung carcinoma

Liang Zhang Department of Oncology, The Second Affiliated Hospital of Nantong University, Nantong - 226001, Jiangsu, PR China
Lianglan Shen Department of Nephrology, The Second Affiliated Hospital of Nantong University, Nantong - 226001, Jiangsu, PR Chin
Dijun Wu Department of Radiotherapy, The Second Affiliated Hospital of Nantong University, No.6 of Haierxiang North Road, Nantong 226001, Jiangsu, PR China https://orcid.org/0000-0003-1009-0137

DOI: https://doi.org/10.18388/abp.2020_5498

Abstract

The identification of side population (SP) cells in several cancer studies has been proved to be involved in the treatment failure (chemotherapy) and tumor relapse. Here we have sorted 7% of side population (SP) cells from lung adenocarcinoma by Hoechst 33342 dye expulsion method. Further, the characterization of sorted SP cells showed cancer stem like properties such as transcriptional upregulation of stemness genes (OCT-4, SOX2 and NANOG), ATP binding cassette (ABC) transporter protein (ABCG2) and enhanced level of stem cell surface markers such as CD133 and CD44. Therefore, the aforesaid properties of lung adenocarcinoma SP cells play a significant and functional role in tumor invasion, metastasis, chemotherapeutic drug resistance and tumor recurrence in lung cancer.

pdf
html

Published

2021-04-20

Issue

Vol. 68 No. 2 (2021)

Section

Articles

Acta Biochimica Polonica is an OpenAccess quarterly and publishes four issues a year. All contents are distributed under the Creative Commons Attribution-ShareAlike 4.0 International (CC BY 4.0) license. Everybody may use the content following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.